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ARTICLE
High-Throughput Analysis of Promoter Occupancy Reveals
Direct Neural Targets of FOXP2, a Gene Mutated in Speech
and Language Disorders
Sonja C. Vernes, Elizabeth Spiteri, Je´roˆme Nicod, Matthias Groszer, Jennifer M. Taylor,
Kay E. Davies, Daniel H. Geschwind, and Simon E. Fisher
We previously discovered that mutations of the human FOXP2 gene cause a monogenic communication disorder, pri-
marily characterized by difficulties in learning to make coordinated sequences of articulatory gestures that underlie speech.
Affected people have deficits in expressive and receptive linguistic processing and display structural and/or functional
abnormalities in cortical and subcortical brain regions. FOXP2 provides a unique window into neural processes involved
in speech and language. In particular, its role as a transcription factor gene offers powerful functional genomic routes
for dissecting critical neurogenetic mechanisms. Here, we employ chromatin immunoprecipitation coupled with promoter
microarrays (ChIP-chip) to successfully identify genomic sites that are directly bound by FOXP2 protein in native chro-
matin of human neuron-like cells. We focus on a subset of downstream targets identified by this approach, showing that
altered FOXP2 levels yield significant changes in expression in our cell-based models and that FOXP2 binds in a specific
manner to consensus sites within the relevant promoters. Moreover, we demonstrate significant quantitative differences
in target expression in embryonic brains of mutant mice, mediated by specific in vivo Foxp2-chromatin interactions.
This work represents the first identification and in vivo verification of neural targets regulated by FOXP2. Our data
indicate that FOXP2 has dual functionality, acting to either repress or activate gene expression at occupied promoters.
The identified targets suggest roles in modulating synaptic plasticity, neurodevelopment, neurotransmission, and axon
guidance and represent novel entry points into in vivo pathways that may be disturbed in speech and language disorders.
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Neurodevelopmental disorders that disrupt language ac-
quisition tend to be complex at the genetic level, poten-
tially involving a large number of different susceptibility
loci, such that identification of the relevant molecular
pathways remains challenging.1,2 In earlier studies, we dis-
covered that heterozygous mutations of the human
FOXP2 gene (MIM 605317) are responsible for a rare
monogenic communication disorder, primarily character-
ized by difficulties in learning to make the coordinated
sequences of articulatory gestures that underlie speech
(developmental verbal dyspraxia [MIM 602081]).3,4 The
disorder also involves deficits in many aspects of linguistic
processing, affecting both oral and written abilities, across
expressive and receptive domains.5 To date, speech and
language impairments have been documented in two dif-
ferent multigenerational families segregating missense
and nonsense point mutations of FOXP2,3,4 as well as in
several cases of gross chromosomal rearrangements (trans-
locations and deletions) that disturb the integrity of the
FOXP2 genomic locus in 7q31.3,6–8 People who are affected
with Silver-Russell syndrome (MIM 180860), associated
with uniparental disomy of the maternal copy of chro-
mosome 7, can also display verbal dyspraxia, which ap-
pears to relate to reductions in FOXP2 expression.6
FOXP2 encodes a regulatory protein belonging to the
forkhead-box (FOX) group of transcription factors.3 Mem-
bers of this class of protein share a distinctive type of DNA-
binding motif, the FOX domain, and are prominent reg-
ulators of eukaryotic gene expression, associated with a
wide variety of cellular and developmental processes.9
FOX gene dysfunction has been implicated in a range of
disease states, including developmental eye disorders,
ovarian failure, immune deficiency, and carcinogene-
sis.10,11 Several FOX transcription factors are key players in
CNS development; for example, Foxg1 regulates prolifer-
ation and differentiation of progenitor cells of the telen-
cephalon,12 whereas Foxb1 is critical for normal develop-
ment of diencephalon and midbrain.13 FOXP2 itself be-
longs to a functionally divergent subgroup of the FOX
proteins, characterized by a shorter DNA-binding domain
and the presence of other defining motifs, including glu-
tamine-rich stretches, dimerization domains, and an
acidic C-terminus.14
Much of our current knowledge of the neural correlates
of FOXP2 disruption comes from intensive phenotypic
studies of a single human family (the “KE” family) in
which 15 people have verbal dyspraxia due to a missense
mutation in the FOX domain.3 The mutation in this fam-
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ily is associated with bilateral abnormalities in gray-matter
density, including significant decreases in the inferior
frontal gyrus (including Broca’s area), caudate nucleus,
and cerebellum and increases in the posterior temporal
gyrus (including Wernicke’s area), angular gyrus, and pu-
tamen,15 as well as altered patterns of neural activity dur-
ing linguistic processing.16 Intriguingly, the neural sites of
structural and/or functional abnormalities in the KE fam-
ily are concordant with regions of high FOXP2 expression
in the developing human brain.17 We recently used human
cell lines to demonstrate that the KE family’s missense
mutation and a nonsense mutation causing verbal dys-
praxia in a second multiplex family4,18 dramatically inter-
fered with transcription factor function.18
Overall, the combined findings from phenotypic eval-
uation, neuroimaging studies, expression analyses, and
functional genetic assays suggest that a reduced dosage of
functional FOXP2 has an impact on the development and
function of a subset of distributed neural circuits, includ-
ing those important for speech and language acquisition.
Thus, the FOXP2 gene provides a unique molecular win-
dow into the neural basis of human communication.19 In
particular, its role as a transcription factor, modulating the
expression of target genes, offers elegant functional ge-
nomic routes for dissecting the associated neurogenetic
pathways. However, at present, there are no neural targets
of FOXP2 reported in the literature.
The aim of the present study was to discover down-
stream targets directly regulated by FOXP2 in neurons, by
exploiting emerging strategies based on the chromatin-
immunoprecipitation (ChIP) method. This is a powerful
technique for studying protein-DNA interactions inside
the nucleus under physiological conditions,20 allowing
characterization of genomic sites bound by a protein of
interest in the native chromatin of living cells. Here, we
develop FOXP2 ChIP, couple it to high-throughput screen-
ing of microarrays (ChIP-chip), and identify occupied pro-
moters in native chromatin of human neuron-like cells.
We focus on a subset of targets uncovered via this ap-
proach, demonstrating that altered FOXP2 levels yield sig-
nificant changes in their expression and that FOXP2 binds
in a specific manner to consensus sites within the relevant
promoters. Finally, we identify significant quantitative dif-
ferences in target expression in the embryonic brains of
mutant mice, mediated by specific in vivo Foxp2-chro-
matin interactions. This work, along with that of Spiteri
et al.,21(in this issue) represents the first identification and val-
idation of neural targets regulated by FOXP2 and suggests
roles for this gene in modulating synaptic plasticity, neu-
rodevelopment, neurotransmission, and axon guidance.
Material and Methods
Cell Culture and Reagents
SH-SY5Y cells were grown in Dulbecco’s modified Eagle medium
(DMEM):F12 media (Sigma), and HEK293T cells in DMEM media
(Sigma). Media was supplemented with 10% fetal calf serum
(Sigma), 2 mM L-glutamine (Sigma), and 2 mM penicillin/strep-
tomycin (Sigma). Cells were grown at 37C in the presence of 5%
CO2. Stable SH-SY5Y cell lines overexpressing FOXP2 or nonex-
pressing controls were generated by transfection with pcDNA3.1/
FOXP2 (isoform I–untagged) or the empty vector, respectively, by
use of Lipofectamine Plus (Invitrogen) in accordance with the
manufacturer’s instructions. Cells were cultured in complete me-
dium supplemented with 500 mg/ml G418 (Calbiochem) as a se-
lective agent. Resistant single colonies were isolated 20 d after
transfection and then were cultured and expanded independently
in the presence of G418 (500 mg/ml). Quantitative RT-PCR (qRT-
PCR) (see “qRT-PCR” section) and western blotting (performed as
described elsewhere18) confirmed expression of recombinant
FOXP2. A clone with a high and consistent level of expression
was chosen for use in further experiments. Transient transfections
of SH-SY5Y or HEK293T cells were performed using Transfast (Pro-
mega) or GeneJuice (Novagen) transfection reagents, respectively,
in accordance with the manufacturer’s instructions and were har-
vested 48 h after transfection. FOXP2 detection was performed
using N-terminal (Santa Cruz Biotechnology) or C-terminal (Ser-
otec) goat polyclonal antibodies.18
ChIP
SH-SY5Y cells stably expressing FOXP2 isoform I were cross-linked
using 1% formaldehyde in cross-linking buffer (50 mM HEPES,
100 mM NaCl, 1 mM EDTA, and 0.5 mM ethylene glycol tetra-
acetic acid [EGTA]) at room temperature. Cells were incubated
for 10 min in ice-cold ChIP lysis buffer (10 mM Tris, 0.25% Triton
X-100, 10 mM EDTA, 0.5 mM EGTA, and protease inhibitors) and
were centrifuged at 10,000 g at 4C for 5 min to pellet nuclei.
Nuclei from cells were resuspended in 1 ml Sonication73# 10
Buffer (10 mM Tris, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA,
and protease inhibitors) with 0.1 g of 212–300-mm glass beads
(Sigma) before undergoing 10 rounds of 20-s sonication pulses at
65% power, with 2 min on ice between each round (with use of
Bandelin SONOPULS HD2070 Ultrasonic Homogenisor and MS72
2-mm titanium tip with 200-mm SS amplitude). Cells were cen-
trifuged at 10,000 g at 4C for 5 min to remove glass beads and
cell debris. Then, 1 mg of FOXP2 N-terminal antibody (Santa Cruz
Biotechnology) was incubated with the sonicated supernatants
in IP buffer (0.1 M Tris, 10 mM EDTA, 150 mM NaCl, 0.2 % Triton
X-100, 1% phenylmethylsulfonyl fluoride, and protease inhibi-
tors), rotating overnight at 4C. Immune complexes were cap-
tured by addition of 5 mg sonicated salmon sperm DNA and 50
ml Protein G–sepharose beads, incubated for 3 h at 4C. Protein
was eluted from beads first by 1.5% SDS buffer (1.5% SDS, 1#
TE [pH 7.5], and 30 mM NaCl) and then by 0.5% SDS buffer
(0.5% SDS, 1# TE [pH 7.5], and 30 mM NaCl), with incubation
of the beads with each in turn at room temperature for 15 min.
Pooled supernatants were incubated at 65C overnight to reverse
cross-links. DNA was isolated via phenol-chloroform extraction
followed by ethanol precipitation. Concentration and purity of
the DNA was evaluated by spectrophotometry, and size was as-
sessed via gel electrophoresis. Protein samples were extracted in
parallel via precipitation with use of trichloroacetic acid (Sigma),
and western blotting was used to confirm immunoprecipitation
of the FOXP2 protein.
In vivo Foxp2 ChIP with use of embryonic brains from wild-
type or homozygous mutant mice was performed according to
the protocol described by Spiteri et al.21(in this issue) In each case,
whole-brain tissue at embryonic day 16 (E16) was pooled from
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Table 1. Genes Displaying Significant
Enrichment ( ) in FOXP2P ! .05
High-Throughput Location Analysis
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
six mice. Mutant mice carry an early nonsense mutation in Foxp2,
which leads to both nonsense-mediated RNA decay and protein
instability, resulting in an absence of detectable Foxp2 protein,
as confirmed using both N- and C-terminal antibodies (M.G., J.N.,
and S.E.F., unpublished data). Wild-type and mutant mice were
littermates, to maximize the homogeneity of the genomic back-
ground. Despite a lack of Foxp2 protein, homozygous mutants
show no gross anomalies in anatomy or brain development dur-
ing embryogenesis. Postnatally, they display developmental de-
lays and reduced cerebellar growth, dying ∼3–4 wk after birth for
as-yet unknown reasons (M.G., J.N., and S.E.F., unpublished
data). All animal studies were performed conforming to the reg-
ulatory standards of the U.K. Home Office, under Project Licence
30/2016.
Ligation-Mediated PCR Amplification of ChIP Products
Purified chromatin was amplified via ligation-mediated PCR in
accordance with published protocols.22 Size and purity of DNA
was assessed via spectrophotometry and gel electrophoresis.
Hybridization of Human FOXP2 ChIP Products
to Promoter Microarrays
Two hundred nanograms of amplified immunoprecipitated chro-
matin or total input DNA was fluorescently labeled with Cy5 or
Cy3, respectively, by use of random primers provided in the
BioPrime DNA labeling system (Invitrogen), in accordance with
the manufacturer’s instructions. The labeling reaction was al-
lowed to proceed for 16 h at 37C, before purification by sodium-
acetate precipitation. A total of 2 mg of labeled DNA was hybrid-
ized to high-density human promoter arrays (Aviva Biosystems).23
Three biological replicates were performed.
Microarray Data Analysis
Array images were scanned using the Axon GenePix 4000B. Data
were retrieved, and initial quality control was performed using
the GenePix Pro 6.0 software package (Molecular Devices). Mi-
croarray data analysis was performed using the Limma package
for R.24,25 Print-tip loess normalization and background correction
was performed within each array. Data were normalized between
arrays by use of quantile normalization, and the median value
was calculated from triplicate experiments for each probe, for use
in further analyses. Probes that displayed statistically significant
differences of abundance ( ) were ranked according to bothP ! .05
fold change and P value. The P values were adjusted for multiple
testing by use of the false-discovery–rate method in the p.adjust
package in R.26 All microarray data can be found in the tab-
delimited ASCII files of data sets 1–5 (online only).
Functional Classification of Genes
The GOTree Machine (GOTM),27 part of WebGestalt (Web-based
gene set analysis toolkit), was used to visualize gene-function
relationships. This program queries the Genekey database incor-
porating the Locuslink, Ensembl, Swiss-Prot, HomoloGene, Uni-
gene, Gene Ontology Consortium, and Affymetrix databases. Sta-
tistical significance of overrepresentation in the target gene list
of 303 genes was calculated using the entire probe set as a ref-
erence data set, via a hypergeometric test, where significance is
defined as . Functional annotation was performed usingP ! .05
the Database for Annotation, Visualization, and Integrated Dis-
covery (DAVID).28
Pathway Network Analysis
Ingenuity pathway analysis software was used to identify inter-
actions between target genes (Ingenuity Systems). All 303 en-
riched genes with a P value !.05 (table 1) were included in this
analysis, and both direct and indirect interactions were consid-
ered. The full set of genes from the array was used as a reference
data set.
Motif Analysis
The top 100 statistically significant probe sequences were assessed
for the presence of known FOX family binding sites by use of the
Emboss FUZZNUC nucleic acid–pattern search tool. Predicted
sites for FOXP2 binding were based on previously published con-
sensus binding sites for FOX family members or recently reported
sequences bound by FOXP2. Sites were defined as follows: for
FOXP2, (A)ATTTG(T) (i.e., AATTTG or ATTTGT)29,30; for FOXP,
TATTTRT14; and, for FOX, TRTTKRY,31 where R p A or G, K p T
or G, and Yp T or C. When a site fell into two classes of motifs,
only the most specific level of classification was used—that is,
sites were preferentially categorized as FOXP2, FOXP, or FOX con-
sensus sites, in that order. Significance was calculated using x2
tests comparing frequencies to counts of predicted sites in per-
muted probe sequences from the top 100 statistically significant
probe sequences. When potential sites for hetero- or homo-
dimerization were considered, only nonoverlapping sites con-
forming to the exact consensus that lay within 100 bp of each
other were included.
Sequences were assessed for the presence of overrepresented
motifs by use of the Multiple Em for Motif Elucidation (MEME)
and/or Motif Alignment and Search Tool (MAST) programs.32,33
Top-scoring matrices were investigated for matches to any known
binding-site matrices by use of the TRANSFAC database. Se-
quences were investigated for coincident motifs that could po-
tentially interact with the function of FOX family binding sites.
A total of 542 binding-site matrices from TRANSFAC were used
to query the enriched probe sequence set (303 genes) (table 1),
as well as the set of sequences from the whole array as a reference
data set. Statistical significance ( ) was assessed using Stu-P ! .05
dent’s t test, to determine the overrepresentation of the binding
sites present in the enriched probe data set compared with the
whole array data set.
qRT-PCR
RNA was extracted from cells or tissue harvested in TRIzol reagent
by use of the QIAGEN RNeasy kit. Human cell-based experiments
exploited SH-SY5Y cells transfected with either FOXP2 or empty
control vectors. For stable transfectants, multiple independent
passages of a single clone were used (see “Cell Culture and Rea-
gents” section), whereas transient transfectants involved sepa-
rately transfected clones. For the latter, cells were harvested 48 h
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Table 2. qRT-PCR Primers
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
after transfection for RT-PCR analyses. In vivo mouse experiments
used dissected brain tissue from E16 embryos, including mutant
mice lacking Foxp2 protein and wild-type littermate controls.
Reverse transcription was performed with Superscript III reverse
transcriptase (Invitrogen) in accordance with the manufacturer’s
instructions. In brief, 1 mg RNA was primed via incubation with
100 ng of random primers and 0.8 mM deoxynucleotide tri-
phosphates (dNTPs) at 65C for 5 min and then on ice for 1 min.
Reverse transcription was mediated via the addition of 200 U of
Superscript III Reverse Transcriptase (Invitrogen) and 20 U of Su-
perase-In RNase Inhibitor (Ambion), in the presence of first-
strand buffer (Invitrogen).
Primers specific for candidate genes and for the control house-
keeping gene GAPDH/Gapdh (glyceraldehyde 3-phosphate de-
hydrogenase) were designed using PrimerBank.34 Human and
mouse primers were as given in table 2. PCRs used SYBR Green
supermix (Bio-Rad), including 0.2 mM each of forward and reverse
primers and 1 ml of cDNA template prepared as described above.
Quantitative PCRs were performed on the iQ5 thermal cycler real-
time PCR detection system (Bio-Rad) in accordance with the man-
ufacturer’s instructions. Reaction conditions were (1) 95C for 3
min, (2) 95C for 15 s, (3) 60C for 30 s, and (4) 72C for 30 s,
then (5) repeat from step 2 for 49 cycles, followed by (6) 95C
for 1 min, and (7) 55C for 30 s. Melting-curve analysis was per-
formed to assess the specificity of the amplification. Data analysis
was performed using iCycler software (Bio-Rad). Quantification
was calculated using the comparative CT method.
35 Fold changes
are reported in response to FOXP2 expression (transient or stable)
compared with cells transfected with an empty vector, following
normalization to an internal control, the GAPDH housekeeping
gene. Reported fold changes for in vitro experiments are the mean
of comparisons between seven (stable) or six (transient) cDNA
preparations. In vivo fold changes are reported as the mean of
comparisons between cDNA preparations from five wild-type and
five knockout littermates. Data are expressed as meanSEM. Sta-
tistical significance was assessed using unpaired t tests (two-
tailed).
qRT-PCR experiments with Slc17a3 in wild-type versus mutant
mice indicated loss of repression in E16 brains and were followed
up with independent replications in separate litters by use of
standard RT-PCR. Samples were prepared and reactions performed
in the same manner as qRT-PCR experiments, except that PCR
cycle number was varied depending on primers: 30 cycles for
Foxp2 and Gapdh and 40 cycles for Slc17a3. In this case, PCR
products were run on 2% agarose gels in the presence of ethidium
bromide to allow visualization of DNA.
Electrophoretic Mobility Shift Assays (EMSAs) for DNA
Binding
HEK293 nuclear extracts (transfected with FOXP2 or an empty
vector control) and purified FOXP2 protein (DQ-rich: amino acids
262–715) expressed in a bacterial system were prepared as de-
scribed in our earlier study.18 HEK293 cells yield higher FOXP2
overexpression than do SH-SY5Y cells, facilitating clean EMSAs.
Probes were designed as 20–28-nt oligomers. A consensus probe,
based on a previously described FOXP1 consensus binding se-
quence, was used as a positive control.14 Oligonucleotide labeling
and binding reactions were performed as described elsewhere.18
When an unlabeled competitor probe was used to confirm spec-
ificity of DNA binding, it was added in 5-fold or 10-fold excess
and was incubated at room temperature for 15 min before ad-
dition of labeled probe. Supershift assays were performed via
preincubation of an N-terminal FOXP2 antibody (Santa Cruz)
with nuclear lysates, for 15 min at room temperature before the
binding reaction. Protein-DNA interactions were resolved on a
5% polyacrylamide Tris/borate/EDTA gel.
Semiquantitative PCR
Chromatin isolated during ChIP from mutant and wild-type
mouse brains was amplified using a semiquantitative PCR tech-
nique. PCR amplification was performed using 10 ng of template
chromatin from each sample, in the presence of 1# Reaction
Buffer (Applied Biosystems), 0.2 mM dNTPs, 2.5 mM MgCl2, 0.375
mM forward and reverse primers, and 0.75 U AmpliTaq Gold DNA
polymerase (Applied Biosystems). A touchdown PCR protocol was
used as follows: (1) 95C for 5 min, (2) 95C for 30 s, (3) 68C for
30 s and 0.5C per second until temperature reaches 55C, and
(4) 72C for 2.5 min, then (5) repeat from step 2 for 14 cycles,
followed by (6) 95C for 30 s, (7) 55C for 30 s, and (8) 72C for
3 min, and then (9) repeat from step 6 for 19 cycles, followed by
(10) 72C for 10 min. PCR products were run on 2% agarose gels
in the presence of ethidium bromide to allow visualization of
DNA. Reactions were performed in triplicate. Primers were as fol-
lows: for Slc17a3, forward 5′-TGGTAACATGTGCAAATTGAGA-3′
and reverse 5′-AATGGACAAAACCCACAAGC-3′; for Cer1, forward
5′-GCTGTGACCAACAGCTTCAA-3′ and reverse 5′-AGATGTCTG-
CCACAGCACAG-3′; for Psen2, forward 5′-CCAGCTTTCCTTGAG-
CTGAC-3′ and reverse 5′-ACAAATGGCACATCGACAGA-3′; and,
for b-actin, forward 5′-AGGGTACCACCGGAAAAGTC-3′ and re-
verse 5′-CCCCAAAGGCTGAGAAGTTA-3′.
Results
Isolation of Promoters That Are Bound by FOXP2
in a Human Neuronal Cell Model
To shed new light on the roles of FOXP2 in normal and
abnormal brain development, we set out to discover direct
neural targets of this transcription factor via ChIP-based
strategies in an appropriate human cell-line. SH-SY5Y cells
have been exploited commonly for many years as a stan-
dard model for investigating human neuronal function36
and were used effectively in a previous investigation to
explore properties of etiological FOXP2 mutations impli-
cated in speech-language disorder.18 For the present study,
we employed stable transfection to generate SH-SY5Y cells
displaying constitutive expression of the 715-aa isoform
of FOXP2 (isoform I) (hereafter, “SH-FOXP2 cells”), in par-
allel with control cells transfected with an empty vector
(see the “Materials and Methods” section). Stable expres-
sion in SH-FOXP2 cells was confirmed at the mRNA level
by use of qRT-PCR and at the protein level via western-
blotting experiments with polyclonal antibodies rec-
ognizing epitopes at the N- and C-termini of FOXP2 iso-
form I.18 Both antibodies were specific to FOXP2 and did
not show cross-reactivity to other highly similar FOX pro-
teins, such as FOXP1 and FOXP4.
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Figure 1. Overview of ChIP-chip technique. Living cells are cross-linked by treatment with formaldehyde to preserve interactions
between transcription factors and target DNA. Following cell lysis, genomic DNA is sheared into fragments of ∼0.5–1 kb. At this stage,
an aliquot is removed to be used as “input” reference DNA. Chromatin fragments are immunoprecipitated using an antibody directed
to the N-terminus of FOXP2. Cross-links are heat reversed in both the immunoprecipitated and input samples. After DNA purification
and labeling with fluorescent dyes, samples are applied to microarrays containing fragments from thousands of human promoters. Genes
whose promoters show positive fold changes can then be investigated using in silico analysis. Functional validation via qRT-PCR expression
analysis and DNA binding assays is performed on a gene-by-gene basis.
FOXP2-specific ChIP was developed using the antibody
recognizing the N-terminus of isoform I. SH-FOXP2 cells
were chemically cross-linked, nuclei were isolated and
treated with sonication to shear DNA, and FOXP2-bound
DNA was enriched via immunoprecipitation. After rever-
sal of cross-links, the resulting DNA fragments were pu-
rified and amplified by ligation-mediated PCR. Initial
characterization of pulled-down fragments via shotgun se-
quencing, followed by PCR-based comparisons with ChIP
with a no-antibody control, indicated that the FOXP2
ChIP protocol was successful in yielding enrichment of
bound sites (data not shown).
We went on to perform location analysis of FOXP2 bind-
ing sites in SH-FOXP2 cells via ChIP-chip,20 by cohybri-
dizing differentially labeled ChIP-enriched and nonenri-
ched (total input) DNA to human promoter arrays (fig. 1).
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Table 3. GO Characterization of the 100 Most Significantly Enriched Genes in FOXP2 High-Throughput Location Analysis
GO Level 1
and Child GO Categories Genes
Signal transducer:
Cell communication STC1,a KCNE1L, TIAM1,a TRAF1,a,b ATF6,a,c EPOR,a CD180,a,d CD5,a PLAUR,a,e ITPK1,b,c,e,f RALBP1, and RAB18c,f
Synaptic transmission/synapse VAMP2, LNPEP,b,d TDO2,b RALA,a,c,d MAPK8IP1,a,e DCTN2, and MAPK7c,e
Notch signaling pathway NCOR2,a,c SNW1,a and PSEN2a
Wnt signaling pathway PM5, CER1,a and SFRP4
G-protein–coupled receptor signaling CXCL2,a,d CCL19,a,d TGM2,b,c,d,e EBI2,d GNAZ,c,f PTGER1, CALCRL, and OPN1SWd
Development: HOXB6c and MAEA
Nervous system development NEUROD2,c SPOCK1,b and PAX3c
Organ development/morphogenesis TCF12,c LECT1, CD164,d,g SYK,a,c,e,d,g DGAT1,e PAX1,c FLT1,c,e,g TAGLN,a and SPEGc,e
Binding:
Ion binding PYCR1,c,f RFPL3,a RCN2,a DUSP12,c,f TPO,d SOD3, and ACSL5
Nucleic acid/nucleotide binding SNFT,a RPL22, RPL28, EIF3S10, RAD51AP1,a,d TOPBP1,a LBR,a PCCA, TUBB2B,f PEX1,f FMO4,d and SMC2a,f
Protein binding TNNI1, SMARCB1, ALDOA, HSPB7,d PSMD1, and C13orf24
Transporter activity: SLC2A4a and ERO1L
Ion transporter COX11,b SLC17A3,b CACNG3,b FTH1,a SLC20A1,g TRPA1, SLC25A3, SLC4A8, and SLC22A14
Catalytic activity: IFI30d and LDHAa
Transferase FTSJ2, PIGC, FUT2, ST3GAL5, and PTK9a
Hydrolase HYAL2, TLL2, PSMA3,a and TPP2
Cell adhesion SSX2IP,a HAS1,e SORBS3,a HAPLN1, and HRSP12f
Cellular process:
Response to stimulus IGLL1
NOTE.—Genes classified as being in additional categories are indicated with the following footnotes.
a Protein binding.
b Ion binding.
c Nucleic acid/nucleotide binding.
d Response to stimulus.
e Transferase.
f Hydrolase.
g Cell communication.
The experiments involved high-density microarrays
(Aviva Biosystems) including PCR products from almost
5,000 well-characterized promoters. The DNA fragments
are an average of ∼900 bp in size and typically span se-
quence from ∼650 bp upstream to ∼250 bp downstream
of each transcription start site (see the work of Li et al.23
for full description of array characteristics). These arrays
were designed in earlier studies for the specific purpose of
high-throughput location analysis and have been used
successfully to identify binding sites of other important
transcription factors.23
ChIP-chip experiments in SH-FOXP2 cells identified 303
DNA fragments that were consistently enriched in im-
munoprecipitated material across three independent bi-
ological replicates ( ; see table 1). We performed de-P ! .05
tailed bioinformatic analyses of the 100 most significantly
enriched promoters—these encompassed a range of gene
ontology (GO) categories but included many genes rele-
vant to the brain, in particular those involved in neuro-
transmitter release, G-protein–coupled receptor signaling,
the Notch and Wnt signaling pathways, ion transport
and/or binding, and nervous-system development (table
3). Empirical analyses of statistical significance (permu-
tation-based simulations; see the “Material and Methods”
section) indicated that this subset of promoters includes
a large excess of positive findings beyond those expected
to occur by chance (false-discovery rate ∼22%).
Identification of Biological Themes Associated
with FOXP2 Binding
We performed in silico analyses of our set of significantly
enriched target promoters using WebGestalt.27 These tools
help to identify the GO categories and biological themes
that characterize a set of genes and that are significantly
overrepresented in the data set compared with an unbi-
ased reference set (in this case, all the genes represented
on the promoter arrays). We used this program to build
GOTrees, graphical representations of the relationships be-
tween the overrepresented gene categories. GO categories
are divided into three separate classifications: cellular
compartment, biological process, and molecular func-
tion.37 With regard to cellular compartment, a particularly
large proportion of the putative FOXP2 targets identified
by ChIP-chip encode membrane-bound proteins, signifi-
cantly more than would be expected by chance (data not
shown). Notably, biological processes related to homeo-
stasis, locomotory behavior, and axon guidance were sig-
nificantly overrepresented in our data set, as well as mo-
lecular functions, such as ion-transporter activities, kinase
binding and/or activity, and Notch binding (fig. 2).
To further clarify the functional networks related to
FOXP2 binding, we searched for connectivity between pu-
tative target genes, using Ingenuity pathway-analysis soft-
ware. This software exploits a highly comprehensive cur-
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Figure 2. GO clustering of genes enriched in FOXP2 high-throughput location analysis. GOTrees demonstrate GO classifications that
were overrepresented in the target list of 303 genes and relationships between categories, with regard to molecular function and
biological process. Significantly overrepresented categories ( ) are highlighted in black.P ! .05
ated database established from the literature to determine
direct and indirect interactions between genes of interest,
thereby identifying canonical pathways associated with a
particular set of genes. Several networks were generated
(fig. 3 and data not shown), representing functional re-
lationships implicated in development (including embry-
onic and nervous-system development), neurogenesis, cell
death, cell migration, and transcription. Figure 3 shows
one such network that centers largely on the Wnt/b-
catenin and IGF-1 signaling pathways.
Bioinformatic Characterization of Binding Sites
in Enriched Promoters
The set of 100 enriched target promoters were investigated
in silico for the presence of FOXP2 consensus binding sites.
This analysis focused specifically on the ∼1 kb of each
promoter represented on the Aviva arrays. As shown in
figure 4A, we searched for three categories of binding sites,
which had different levels of specificity: (i) experimentally
determined sites shown to be bound by FOXP2 in struc-
tural studies ((A)ATTTG(T)29,30), (ii) a consensus site deter-
mined in vitro for the closely related family member
FOXP1 (TATTTRT),14 which can also be bound by FOXP2,18
and (iii) the general FOX family consensus sequence
(TRTTKRY), to which most FOX proteins are able to bind.31
We refer to these three categories of sites as FOXP2, FOXP,
and FOX, respectively. (Note that the FOXP consensus se-
quence also conforms to the general FOX family consen-
sus, but each site was classified only once, on the basis of
the category that gave the most specific match.)
Figure 4A displays the numbers of target promoters con-
taining consensus binding sites for each category, includ-
ing overlap where multiple binding sites from alternative
classes are present in the same sequence. Of note, the
majority of the enriched promoters (70 of 100) contain at
least one exact match to the consensus site for FOXP2,
FOXP, or FOX, and a substantial number of these (43)
include multiple sites from the different categories. In ad-
dition, multiple sites from the same category were often
present within a single sequence. For example, 78 perfect
FOXP2 consensus binding sites were identified within 40
of the top 100 enriched sequences. Using simulations, we
determined that the probability of finding each of these
FOXP2 consensus sites by chance was !0.01 (see the “Ma-
terial and Methods” section). The numbers of sites and
the statistical significance for all consensus binding sites
that we identified are given in figure 4B. When criteria
were relaxed to allow a single mismatch at any position,
all sequences displayed the presence of a FOXP2 binding
site. Unlike most other forkhead proteins, FOXP2 is
thought to require dimerization (either with itself or with
other members of the FOXP subfamily) to bind target
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Figure 3. Network analysis of target genes. Interaction networks were generated using Ingenuity pathway analysis. The figure shows
one example of an important functional pathway identified via this approach, which centers on Wnt/b-catenin and IGF-1 signaling
pathways. Genes shaded in gray were identified as significantly ( ) enriched in ChIP-chip analyses; others were brought into theP ! .05
pathway on the basis of relationships within the Ingenuity knowledge database. Solid and dotted lines represent direct and indirect
interactions, respectively. Node shapes represent the class of molecule—vertical diamonds represent enzymes, horizontal diamonds
represent peptidases, ovals represent transcription factors, squares represent cytokines, triangles represent kinases, hexagons represent
translation factors, and circles represent other classes. Further information can be found at the Ingenuity Systems Web site.
DNA.14,38 We searched the putative target sequences for
regions that could provide an opportunity for binding of
FOXP dimers, focusing only on perfect consensus matches
that were within 100 bp of each other. We thereby iden-
tified 29 independent compound sites involving the same
category of binding site, as well as 37 compound sites
involving different categories.
We next investigated the potential for other transcrip-
tion factors to regulate these target genes. We determined
whether there was overrepresentation of other known
transcription factor binding sites, since this could suggest
a direct or indirect role in regulation of gene expression
by FOXP2 (e.g., as part of a transcriptional complex). We
used two approaches to query the TRANSFAC database.
First, we searched all 303 (significantly enriched) se-
quences for the presence of known TRANSFAC binding-
site matrices and determined significant overrepresenta-
tion on the basis of the frequency of these sites in all
sequences represented on the array. A total of 28 consen-
sus motifs, recognized by 21 different transcription fac-
tors, were identified as being significantly overrepresented
(described in table 4). Consensus binding sites for tran-
scription factors known to play key roles in neuronal plas-
ticity and CNS development—such as CREB and its related
family member, ATF, as well as SP1 and PAX5—were found
significantly more often in the target list than would be
expected on the basis of the sequences represented on the
array. Second, we independently used an unbiased ap-
proach to identify the presence of significantly overrepre-
sented sequence motifs in our data set by useof the MEME
algorithm.32,33 The resulting matrices were investigated for
matches to known binding sites in the TRANSFAC data-
base. Three of the overrepresented matrices showed the
closest consensus to known binding sites (fig. 4C). Nota-
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Figure 4. In silico motif analysis of sequences enriched in FOXP2
ChIP-chip. A, Assessment of the presence of known FOX (TRTTKRY),
FOXP (TRTTTRY), or FOXP2 ([A]ATTTG[T]) binding sites in the pro-
moter regions of the genes in table 3. The Venn diagram represents
the number of promoter sequences containing at least one of these
binding sites, including overlaps where more than one class of
site is present in the same sequence. Of the promoters, 70 con-
tained at least one perfect FOXP2, FOXP, or FOX binding site, with
most (61%) containing multiple classes of consensus sites. All
promoters featured at least one FOXP2 binding site that contained
a single mismatch. B, Number and significance of binding sites.
The total number of binding sites identified in all sequences is
represented, partitioned according to the site class and the sta-
tistical significance of identifying each site within the data set.
NS p not significant. C, Results of unbiased motif analysis. Ov-
errepresented motifs identified from the 100 target sequences an-
alyzed included motif 1, which closely resembled the FOX family
consensus binding site, and motifs 2 and 3, which were close or
exact matches to the UBP1 (also known as “LBP-1a”) consensus
binding site.
bly, motif 1 represented a close match to the FOX family
consensus binding site, and motifs 2 and 3 were near or
exact matches for the upstream binding protein 1 (UBP1;
also known as “LBP-1a”) transcription factor binding site.
UBP1 is a CCAAT-binding protein that is able to act in a
heterodimer with its closely related family member, LBP-
1c.39 The LBP-1c binding site was also found to be signif-
icantly overrepresented in the target gene sequences (table
4). These data raise the possibility that there may be some
functional interaction between FOXP2 and the transcrip-
tion factors detailed above (and in table 4)—that is, via
direct interactions or indirectly as part of a larger complex.
Significant Alteration of ChIP Target Expression
Due to Increased FOXP2 Expression
Our ChIP-chip experiments successfully identified pro-
moter sites that are enriched for FOXP2 binding in the
native chromatin of living SH-SY5Y cells. We went on to
obtain functional verification for a subset of genes from
table 3, using multiple independent approaches (figs. 5
and 6). First, we directly assessed the evidence of a func-
tional link between FOXP2 and selected ChIP targets, by
asking whether presence or absence of FOXP2 protein led
to significant changes in expression of the gene in ques-
tion. These experiments exploited our SH-SY5Y cell lines
that had been stably transfected with either FOXP2 or an
empty vector control and involved quantitative assess-
ments of ChIP-target mRNA expression on a gene-by-gene
basis with use of qRT-PCR (fig. 5). We thereby identified
robust and significant differences in ChIP-target expres-
sion. Of the 14 ChIP targets investigated in figure 5A, 11
genes displayed significant effects, across replicate exper-
iments. In line with previous studies suggesting that FOXP
proteins act as repressors,14,18,38 10 of the targets tested
(SLC17A3, CALCRL, LNPEP, HSPB7, CER1, COX11, PM5,
PSEN2, CD164, and RCN2) showed reduced expression in
the presence of FOXP2. However, two genes (MAPK8IP and
SYK) displayed significant increases in transcription in re-
sponse to FOXP2 upregulation in our stable cell lines, sug-
gesting that the protein may also act as an activator for a
minority of direct targets. Targets that showed altered gene
expression were also assessed in multiple additional bio-
logical replicates involving transient transfections of SH-
SY5Y cells. As shown in figure 5B, several of the targets
that were functionally validated in the stable cell models
showed similarly significant effects during multiple in-
dependent transient transfections.
Direct Sequence-Specific Binding of FOXP2 to Promoters
of Validated Targets
In the next stage of functional verification, we aimed to
identify the particular sites within each target promoter
that are directly bound by FOXP2 and to assess the spec-
ificity of the protein-DNA interaction. For this step, we
focused on nine of the ChIP targets that had already
shown evidence of up- or down-regulation in response to
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Table 4. Significantly Overrepresented Co-Occurring Transcription Factor Binding Motifs
Name (Description)
and TRANSFAC Matrix Consensus Sequencea P
AP-2 (activator protein 2):
AP2_Q6 MKCCCSCNGGCG !.01
AP-4 (activator protein 4):
AP4_01 WGARYCAGCTGYGGNCNK !.01
AP4_Q6 CWCAGCTGGN !.01
ATF1 (activating transcription factor):
ATF_01 CNSTGACGTNNNYC !.01
CAAT (CCAAT box):
CAAT_01 NNNRRCCAATSA !.01
TFCP2 (transcription factor CP2 [also known as “LBP-1c”]):
CP2_01 GCHCDAMCCAG !.01
CREB (cAMP-response element-binding protein):
CREB_02 NNGNTGACGTNN !.01
CREB_Q2 NSTGACGTAANN !.01
CREB_Q4 NSTGACGTMANN !.01
CREBP1 (CRE-binding protein 1):
CREBP1_Q2 VGTGACGTMACN !.01
E47:
E47_01 VSNGCAGGTGKNCNN !.01
GATA1 (GATA-binding factor 1):
GATA1_01 SNNGATNNNN !.01
GATA2 (GATA-binding factor 2):
GATA2_01 NNNGATRNNN !.01
GC box (GC box elements):
GC_01 NRGGGGCGGGGCNK !.01
Ik-2 (Ikaros 2):
IK2_01 NNNTGGGAWNNC !.01
Lmo2 complex (complex of Lmo2 bound to Tal-1, E2A
proteins, and GATA-1, half-site 1):
LMO2COM_01 CNNCAGGTGBNN !.05
MZF1:
MZF1_01 NGNGGGGA !.01
MZF1_02 KNNNKAGGGGNAA !.01
NF1 (nuclear factor 1):
NF1_Q6 NNTTGGCNNNNNNCCNNN !.01
NFY (nuclear factor Y [Y-box binding factor]):
NFY_01 NNNRRCCAATSRGNNN !.05
NFY_C NCTGATTGGYTASY !.01
NFY_Q6 TRRCCAATSRN !.01
Pax-4 (Pax-4 binding sites):
PAX4_01 NGNVGTCANGCGTGNNSNNYN !.01
PAX5 (B-cell specific activating protein):
PAX5_01 BCNNNRNGCANBGNTGNRTAGCSGCHNB !.01
RREB-1 (Ras-responsive element binding protein 1):
RREB1_01 CCCCAAACMMCCCC !.01
Sp1 (stimulating protein 1):
SP1_01 GGGGCGGGGT !.01
SP1_Q6 NGGGGGCGGGGYN !.01
USF (upstream stimulating factor):
USF_Q6_01 GYCACGTGNC !.01
a International Union of Biochemistry ambiguity codes: R p A or G; Y p C or T; K p G or T; M p A
or C; S p C or G; W p A or T; V p A, C, or G; B p C, G, or T; H p A, C, or T; D p A, G, or T; and N p
A, G, C, or T.
FOXP2 in stable SH-SY5Y cell lines (see previous para-
graph) and evaluated binding by use of EMSAs as described
elsewhere.18 For each validated target gene, the sequences
originally represented on the promoter array were
searched in silico to identify the closest matches to FOXP2,
FOXP, and FOX consensus binding sites (see above for
definitions of each category). Oligonucleotide probes
spanning these regions (table 5) were used in EMSAs with
nuclei from human cells overexpressing FOXP2 (fig. 6A
and 6B), and FOXP2-specificity was further confirmed us-
ing purified protein (fig. 6C). Concordant results were seen
for the nuclear extracts and purified protein, with the most
robust and consistent binding seen for probes within
SLC17A3, CALCRL, LNPEP, PSEN2, PM5, CER1, and SYK
promoters. We went on to perform more-detailed analyses
of the protein-DNA interactions for the SLC17A3 probe
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Figure 5. Functional validation of FOXP2 target by expression assays. qRT-PCR was performed for cDNA prepared from stable SH-SY5Y
cell lines (A) or transiently transfected SH-SY5Y cells (B). Expression changes (X-axes) are given as mean of log2 expression ratios of
cells transfected with FOXP2 compared with cells transfected with an empty vector control and are normalized for equal expression of
the internal control, GAPDH. Values are the mean of comparisons of seven independent cDNA preparations for stable cell lines and of
six independent cDNA preparations for transient cell lines. Error bars indicate SEM. P values were calculated using a two-tailed
unpaired t test. Four asterisks (****) indicate , three asterisks (***) indicate , two asterisks (**) indicate ,P ! .0001 P ! .001 P ! .01
and one asterisk (*) indicates . Most expression changes observed in stable cell lines were verified in the transiently transfectedP ! .05
cells. HSPB7 expression could not be detected in transient cell lines; thus, expression changes could not be assessed in this system.
(fig. 6D), demonstrating that binding could be disrupted
by competition with an excess competitor probe but not
if the competitor carried a mutation in the putative core
binding site. Subtle competition by the known FOXP2
binding site could be observed. Binding was not disrupted
by competition with an irrelevant binding site—recog-
nized by NFK but not expected to be recognized by FOXP2.
Moreover, addition of antibodies directed to FOXP2 dis-
rupted the formation of the protein-DNA complexes.
Promoter Binding and Target-Gene Repression In Vivo
in the Embryonic Mouse Brain
We next aimed to demonstrate that validated targets from
functional genomic analyses of neuron-like cell-based
models have biological significance in the CNS in vivo.
We performed in vivo Foxp2 ChIP, using mouse brains at
E16, a developmental time point showing high neural ex-
pression of Foxp2.17 The isolated chromatin could then be
used to assess Foxp2 occupancy at a promoter of interest
via a semiquantitative PCR approach. Crucially, we were
able to compare data from wild-type mouse brains with
those obtained from equivalent experiments in homo-
zygous mutant mice that lack detectable Foxp2 protein,
providing us with an ideal negative control (see the “Ma-
terial and Methods” section). Primers were designed to
amplify promoter regions of the mouse orthologues of
SLC17A3, CER1, and PSEN2, three genes that had been
rigorously tested in our cell-based models. PCR amplifi-
cation of Foxp2 ChIP material from E16 brains indicated
robust enrichments of regions of Slc17a3 and Cer1 pro-
Figure 6. Functional validation of FOXP2 targets by DNA binding. EMSAs were used to determine direct interactions between FOXP2
and the promoter regions of targets already tested in expression assays. Probes were designed on the basis of the region represented
on the promoter array and the presence of FOX(P) consensus binding sites (table 5). A and B, FOXP2 binding to target probes, first
established using nuclei of HEK293T cells. Radiolabeled probes were incubated with either HEK293T nuclei sham transfected with an
empty vector (HEK293 cells express a low level of endogenous FOXP2) or FOXP2 transfected nuclei (indicated by an asterisk [*]). The
position of the shift caused by interaction between FOXP2 and the radiolabeled probe is indicated (arrow). C, Binding to target probes
confirmed via EMSAs with purified FOXP2 protein, which gave results that paralleled those seen in HEK293T nuclei. In panels A–C, the
binding of FOXP2 to a known consensus binding site (CONSENSUS) is shown as a positive control. D, More-detailed analysis undertaken
for SLC17A3-1 probe. Binding assays were performed in the presence of competition from unlabeled probes. FOXP2 binding to the
labeled probe was efficiently impaired via competition with unlabeled competitor probe (SLC17A3) in 5-fold or 10-fold excess, displaying
the specificity of the interaction. Mutation of the core binding site resulted in a lack of competition by unlabeled probes (SLC17A3M),
indicating the importance of the bases for FOXP2 binding. A consensus FOXP2 binding site showed slight competition, whereas an
irrelevant promoter sequence (NFK) was unable to compete in binding at 5-fold or 10-fold excess. Addition of an antibody directed to
FOXP2 (Ab) disrupted complex formation. This confirmed that the identity of the protein causing gel retardation is FOXP2, a result that
was further verified using purified FOXP2 protein.
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Table 5. Probes Used for EMSA DNA Binding Assays
Gene or
Transcript Probe Sequencea
Positionb
(bp) Boundc
Class of Binding Sited
FOXP2 FOXP FOX
Consensus agcttTATTTATgttgttttgtat … No   
PM5-1 ctttaagAATTTGTgtaagc 643 Yes   
PM5-2 gacgggagATTTTGTtgtg 360 No   
CALCRL-1 cacagATTTGTtagattttttttc 436 No   
CALCRL-2 aataTATTTATtctaagtag 232 Yes   
SYK-1 caaagccTTTTGTaataattaaag 565 Yes   
SYK-2 ggtttAATTTATTTGgttgtgg 616 No e  
MAPK8IP1-1 gcctcccAATTTCaggtgag 255 No   
MAPK8IP1-2 tgcTATTGTCccatttcacag 499 Yes   
CER1 gaaggatgttAATTTTtttg 603 Yes   
CER1M gaaggatgttAACCCTtttg … No   
SLC17A3-1 gaataTAGTTATctCTTTGTcc 626 Yes   
SLC17A3-1M gaataTAGGGATctCGGGGTcc … No   
SLC17A3-2 ccATTTCTtaaccTATGTATgat 602 No   
SLC17A3-3 ttttgtatAATTTGagaa 489 Yes   
PSEN2-1 gggcgTTTTGTtcttcttctc 193 No   
PSEN2-2 ccccTGTTTATTGCcttaataag 224 Yes   e
LNPEP-1 tctgtgttTATTTATggtctg 416 Yes   
LNPEP-2 ATTTATggtcTGTTTCTggaatg 407 No   
COX11-1 cgggtaAGTTTGcgtt 136 No   
COX11-2 tcgcgagATTTGAcctctcg 10 No   
NFK ccgggggtgatttcactccccg … No   
a Core binding sites are represented in capital letters. Bases in bold font indicate de-
viation from or mutation of the consensus binding site.
b Position relative to transcriptional start site.
c Ability to be bound by FOXP2 during EMSA.
d A plus sign () indicates the presence of the consensus binding site, and a minus
sign () indicates the absence of the site.
e Indicates two overlapping sites.
moters in chromatin isolated from wild-type mice, com-
pared with that isolated from mutant littermates lacking
Foxp2 protein (fig. 7A). Enrichment was not observed for
the Psen2 promoter or b-actin negative control promoter
region.40
Finally, we investigated whether the in vivo binding of
Foxp2 to Slc17a3 and Cer1 promoters in E16 mouse brain
has detectable effects on target-gene expression in the tis-
sue in question. Our RT-PCR–based expression analyses
detected Slc17a3 expression in the brains of E16 mouse
embryos but at very low levels. Intriguingly, we found that
mutant mice lacking Foxp2 protein demonstrate a sub-
stantial and highly significant increase in Slc17a3 expres-
sion in E16 brain tissue (fig. 7B and 7C). Only minor dif-
ferences in overall Cer1 expression levels were seen be-
tween wild-type and mutant mouse brains. The Slc17a3
expression data are notably concordant with our earlier
human cell-based findings, which showed that human
FOXP2 severely down-regulates SLC17A3 expression in
SH-SY5Y systems (c.f. fig. 5). The corresponding in vivo
findings indicate that Foxp2 normally binds to the Slc17a3
promoter in the embryonic mouse brain, acting to repress
its transcription, and that absence of Foxp2 in mutants
leads to a dramatic loss of repression.
Discussion
Binding of FOXP2 to Promoters of Genes Involved in Cell
Communication, Development, and Ion Transport
in Living Neuron-Like Cells
It is well established that FOXP2 disruptions are correlated
with abnormalities in acquisition of speech and language
skills.3,4,6–8 However, the precise functions of this gene at
molecular, cellular, and developmental levels have re-
mained largely elusive in the 6 years following its discov-
ery. In the present study, we have exploited a powerful
functional genomics approach to gain entry into FOXP2-
related networks and to begin to bridge the gaps between
genes, brain, and behavior. To examine these pathways,
we assessed the binding of FOXP2 to native chromatin in
living neuron-like cells cultured in the laboratory and si-
multaneously screened thousands of promoters through
a microarray-based approach. In this way, we were able to
demonstrate significant enrichment during ChIP-chip ex-
periments for promoters from a range of genes involved
in diverse biological functions, including (but not limited
to) synaptic transmission, cell signaling, ion transport, and
development. As for other transcription factors, FOXP2
may be involved in the regulation of a large number of
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Figure 7. Foxp2 binding to target gene and regulation of target-
gene expression in vivo in embryonic mouse brain. A, Analysis of
in vivo promoter occupancy. FOXP2 ChIP was performed using
whole brains at E16 from either wild-type mice (WT) or homozygous
mutant littermates (MUT) that lack Foxp2 protein as a consequence
of an exon 7 nonsense mutation (see the “Material and Methods”
section). DNA was PCR amplified using primers directed toward
Slc17a3, Cer1, Psen2, or b-actin control promoter regions. The pro-
moters of Slc17a3 and Cer1 were specifically enriched in ChIP sam-
ples isolated from wild-type brains compared with those from mu-
tant brains. Gels are representative of results from triplicate
experiments. IP represents the immunoprecipitated sample. B, Ex-
pression of Slc17a3 showing an inverse relationship with Foxp2
expression in E16 mouse brains. RT-PCR was performed with cDNA
generated from five wild-type versus five mutant whole-brain sam-
ples. Note that reduced expression of Foxp2 in mutant mice is the
result of nonsense-mediated RNA decay; in addition, the potential
truncated product is highly unstable, leading to a lack of detect-
able Foxp2 protein (M.G., J.N., and S.E.F., unpublished data). Ex-
pression changes are represented as mean of log2 expression ratios
for comparisons between wild-type and mutant mice normalized
for equal expression of the internal control, Gapdh. Statistical
significance was calculated using a two-tailed unpaired t test. Two
asterisks (**) indicate ; four asterisks (****) indicateP ! .01
. C, Confirmation of in vivo expression changes in in-P ! .0001
dependent mouse samples. Standard RT-PCR with use of samples
prepared from an independent pair of wild-type and mutant mouse
brains shows a clear loss of repression of Slc17a3 in the mutant.
different genes; on the basis of the empirical analyses of
significance in the array experiments, we would expect a
minimum of 1.5% of promoters in the human genome
(i.e., at least several hundred genes) to be occupied by
FOXP2 in our cell-based models. This estimate is consis-
tent with in vivo human data obtained from human fetal
brain and lung in an accompanying study by Spiteri et
al.,21(in this issue) which, despite the use of a different FOXP2
antibody, identified a highly significant overlapping list
of targets, providing a large degree of independent con-
firmation of targets identified here (discussed further
below).
Several key biological themes and functional pathways
emerged when FOXP2-enriched targets from neuron-like
cells were analyzed for gene-gene connectivity or over-
representation of GO classes. For example, in terms of
biological process, we observed an excess of genes con-
tributing to axon guidance and homeostasis, whereas mo-
lecular functions such as anion transporter activity, notch
binding, and kinase binding and/or activity were also sig-
nificantly overrepresented. Moreover, in silico analyses of
direct and indirect interactions between FOXP2-enriched
targets highlighted a number of interesting networks,
most notably one that was associated with Wnt/b-catenin
and IGF-1 signaling pathways (fig. 3). Intriguingly, genes
represented in this particular network have been impli-
cated in differentiation of neurons and neuroglia, neu-
ronal cell death, cell adhesion, and control of transcrip-
tion. In addition, abnormalities in IGF-related pathways
are thought to contribute to Silver-Russell syndrome, a
disorder that is sometimes associated with reductions in
FOXP2 expression.6
One advantage of assessing gene-gene interaction net-
works is that characterization can be based not only on
the functions of target genes but also on those of inter-
acting genes. Thus, targets can be clustered around func-
tional “nodes” that may not be included in the target list
itself, as shown for CTNNB1 (b-catenin) in figure 3. Of
note, many of the networks uncovered by Ingenuity path-
way analysis were similarly highlighted during GO anal-
ysis, including Wnt/Notch signaling and development.
Wnt signaling plays a major highly conserved role in brain
patterning in vertebrates and invertebrates, including
humans.41,42 Given the role of Wnt genes in patterning the
forebrain in mammals, targets in this pathway are attrac-
tive candidates for mediating structural and functional
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alterations in the brains of people carrying FOXP2
mutations.
Furthermore, we observed significant overrepresenta-
tion of a number of transcription factor binding sites in
the enriched target sequences ( ). This includedP ! .05
binding sites for transcription factors involved in pro-
cesses such as neurodevelopment, Wnt signaling, and
plasticity (CREB, SP1, PAX5, and E47/TCF3),43–48 as well as
genes implicated in disease states, such as Alzheimer dis-
ease (LBP-1c).49 The co-occurrence of these binding sites
highlights the potential interplay of FOXP2 with key path-
ways involved in neural development and function.
After identifying promoters bound by FOXP2 in cell-
based models of neural function, we went on to show, in
these same cells, that quantitative expression levels of pu-
tative target genes could be significantly altered by pres-
ence or absence of FOXP2. Until now, FOXP2 has been
assumed to act as a transcriptional repressor, largely on
the basis of experiments involving expression from arti-
ficial or viral promoters in vitro.14,18,38 Indeed, the majority
of the direct targets validated in the current investigation
showed significant reductions in mRNA expression as a
consequence of increased FOXP2 levels, consistent with
the repressor hypothesis. However, a minority showed up-
regulation in response to increases in FOXP2, suggesting
that, although this regulatory factor usually represses tran-
scription, it is also able to switch from repressor to acti-
vator under certain circumstances. This is consistent with
findings from a number of FOX family members, includ-
ing the closely related FOXP3 protein, which have the
capacity to mediate both repression and activation of
direct transcriptional targets.40,50,51 The switch from re-
pressor to activator may be dependent on binding-site af-
finity,52 cofactors that interact with FOXP2,53 or posttran-
slational modification status. Interaction with cofactors is
particularly pertinent when considering FOXP2 regulation
of gene expression, given that it requires dimerization for
efficient DNA binding. Thus, the expression levels of
known binding partners, such as FOXP family mem-
bers,14,38 CTBP1,38 NFAT,30 or other as-yet unidentified in-
teractors, could affect not only the affinity for the target
DNA but also the switch from repressor to activator.
Overlap of FOXP2 Targets in Cultured Neuron-Like Cells
and Those Identified in Human Fetal Brain
The present report demonstrates the power of extrapolat-
ing from cell-based models to gain insights into brain
function. By using state-of-the-art functional genomics in
cultured neuron-like cells, we uncovered regulatory mech-
anisms that we could subsequently confirm in vivo in the
developing mouse brain (see below). Moreover, in a sep-
arate investigation performed in parallel to our own, Spi-
teri et al. applied ChIP-chip with FOXP2 in vivo by using
human fetal brain tissue.21(in this issue) A between-study com-
parison of the lists of enriched promoters, obtained using
equivalent statistical thresholds ( ; see table 1), re-P ! .05
veals a remarkable degree of overlap in targets suggested
by cell-based and in vivo methods: 29% of putative target
promoters identified by Spiteri et al. in the basal ganglia
(BG) and 30% of those found in the inferior frontal cortex
(IFC) were independently highlighted in SH-SY5Y cells in
the present study, representing 14%–19% of our potential
targets (table 1). The probabilities of obtaining this extent
of overlap by chance are highly significant ( [BG/24P ! 10
SH-SY5Y] and [IFC/SH-SY5Y]). The concordance22P ! 10
between these data sets is particularly striking when it is
considered that the cell-based and in vivo ChIP-chip stud-
ies employed antibodies recognizing distinct epitopes at
opposite termini of the FOXP2 protein and that these an-
tibodies have the potential to recognize different sets of
alternatively spliced isoforms.
Like us, Spiteri et al.21(in this issue) were able to confirm reg-
ulation of ChIP targets by FOXP2 with use of cell-based
models and similarly found that this transcription factor
can act as both a repressor and an activator. Interestingly,
although some targets that were commonly tested showed
equivalent expression changes (e.g., HSPB7 and PM5) in
the independent studies, others (e.g., CALCRL) were sig-
nificantly activated in one study but were significantly
repressed in the other. We retested CALCRL expression
levels with use of the primers detailed by Spiteri et al.
(unpublished data) to determine whether differences be-
tween studies were caused by detection of alternative tran-
scripts. However, in our cells, these primers detected ex-
pression changes that were entirely consistent with our
previous experiments (data not shown and fig. 5). Instead,
the differing effects between studies may relate to the spe-
cific cellular models that were used. Although both in-
vestigations employed SH-SY5Y cells, the present study
assessed expression in replicates of a stably transfected cell
line generated from a single progenitor. This clonal line
provided a homogenous population in which every cell
expressed a consistent and relatively low level of FOXP2
over successive passages. By comparison, the study by Spi-
teri et al. used a more heterogeneous cell population.
These findings may again indicate that the relative levels
of FOXP2 and its interacting cofactors affect the protein’s
ability to act as an activator or repressor and provide fur-
ther evidence of the complexity of regulatory mechanisms
mediated by the FOXP subgroup.40,51
Identification by Human ChIP-Chip of Conserved Pathways
Regulated by Foxp2 in Vivo in Embryonic Mouse Brain
It is thought that orthologues of the FOXP2 gene play
highly conserved roles in development and/or function
of sensorimotor-related circuits in many vertebrates, on
the basis of similarities in sequence and neural expression
patterns across a range of distantly related species.19,54 As
such, studies of animal model systems can offer important
clues to FOXP2 function at multiple levels, in ways that
are not possible when humans are investigated.55 In par-
ticular, there is a high degree of sequence conservation
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between human FOXP2 and its mouse orthologue
(∼99.4% identity at the amino acid sequence level), and
there is notably concordant expression in corresponding
brain structures, with consistent patterns of sublocaliza-
tion.17 We recently generated mutant mice that carry an
early stop codon, making them effectively null for Foxp2
(M.G., J.N., and S.E.F., unpublished data). The availability
of homozygous mutant animals that completely lack
Foxp2 protein provides a valuable system for establishing
whether targets identified in cell-based studies also show
promoter occupancy and/or mRNA regulation by Foxp2
in vivo in the CNS.
Thus, in the present study, we followed up human ChIP-
chip by performing Foxp2 ChIP in embryonic brain tissue
(E16) from wild-type and mutant mice and assessed en-
richment of promoter regions for three of our most prom-
ising targets. We were able to demonstrate clear in vivo
promoter occupancy for Slc17a3 and Cer1 but not for
Psen2. These data show interesting parallels with inde-
pendent in vivo ChIP data from human fetal brain ob-
tained by Spiteri et al., by which SLC17A3 and CER1 were
identified as potential targets in human BG and IFC, re-
spectively, and binding to the PSEN2 promoter was not
noted in either region. We went on to test whether pro-
moter occupancy of Slc17a3 and Cer1 was correlated with
significant alterations in regulation of each target, by com-
paring quantitative expression levels in E16 brains of wild-
type and mutant mice. Cer1 demonstrated only a minor
difference, but Slc17a3 showed a highly significant loss of
repression in absence of Foxp2 protein.
Genes like SLC17A3/Slc17a3 that show promoter oc-
cupancy in vivo in the developing brains of humans and
mice, as well as FOXP2/Foxp2-mediated expression dif-
ferences in both human neuron-like cells and mouse brain
tissue, clearly represent confirmed targets in both species.
Thus, further studies of such targets with use of mouse
mutants will yield critical insights into conserved neural
pathways and how they are disturbed by disruption of
FOXP2/Foxp2. For example, at this stage, there is little
information on the function of SLC17A3, other than that
it is thought to act as a sodium/phosphate cotransporter
and is highly expressed in the kidney and liver.56,57 We
have uncovered low levels of Slc17a3 expression in em-
bryonic brain, which is consistent with online data from
the Cancer Genome Anatomy Project (CGAP)–EST pro-
ject.58 Our findings may indicate a potential, as-yet un-
determined role for this gene in neural pathways regulated
by FOXP2, which could be important for speech and lan-
guage development. Alternatively, loss of repression of
SLC17A3 may lead to inappropriate expression in the
brains of affected individuals, interfering with the normal
development and function of FOXP2-related circuits.
It is worth emphasizing that, given the complex spati-
otemporal patterns of FOXP2/Foxp2 neural expression,17 a
target identified in human neuron-like cells may still rep-
resent a real conserved target even if it does not show
validation of binding and/or regulation in E16 whole
mouse brain. FOXP2/Foxp2 is expressed in tightly regu-
lated subsets of neurons in several structures, including
the striatum, thalamus, deep layers of the cortex, and Pur-
kinje cells of the cerebellum.17 Regulatory effects in sub-
populations of neurons may be diluted out in studies of
whole brain. More crucially, different sets of targets are
likely to be regulated by Foxp2 in distinct subpopulations
and/or at different developmental stages, depending
partly on the presence or absence of cofactors (such as
Foxp1 or Foxp4). In relation to this, it is interesting to
note that Cer1, although bound by Foxp2 in vivo in E16
whole-brain samples, showed only minor changes in over-
all expression in equivalent samples from mutant mice.
In addition, recent ChIP-chip studies, including those in-
vestigating FOXP3 binding,40,51 have highlighted dispari-
ties between transcription factor promoter occupancy and
transcriptional regulation.59 In some cases, target-gene ex-
pression could be validated under altered cellular condi-
tions, where the relevant transcriptional cofactors were
present.59
Finally, it is reasonable to expect that a subset of true
FOXP2 targets will be human specific and hence impos-
sible to validate or characterize in animal models. Indeed,
evidence that FOXP2 was subject to positive selection in
the human lineage suggests that the relevant mechanisms
may have undergone modifications in our species, pos-
sibly in relation to their recruitment toward speech and
language capacities.60,61 Future studies could address the
important issue of species-specific targets, by using in vivo
neural ChIP-chip in different species to facilitate a direct
comparison of genomewide promoter occupancy in the
brains of humans, nonhuman primates, and rodents.
Concluding Remarks
In the present study, we have exploited high-throughput
location analysis of binding sites to identify direct neural
targets regulated by FOXP2, the first gene to have been
implicated in a human speech and language disorder.
Moreover, we have provided compelling evidence at mul-
tiple levels that our findings are relevant to in vivo bio-
logical function. First, the promoters that we identified
contained an excess of sequences conforming to previ-
ously determined consensus sites for FOXP2 binding. Sec-
ond, targets included significant overrepresentations of a
subset of GO categories, suggesting potential roles in mod-
ulating synaptic plasticity, neurodevelopment, neuro-
transmission, and neurite outgrowth. Third, quantitative
expression levels of target genes isolated by ChIP were
significantly altered by presence or absence of FOXP2 in
human neuron-like cells, in both stable and transiently
transfected systems. Fourth, EMSAs demonstrated that
FOXP2 binds directly and specifically to particular sites
within validated target promoters. Fifth, targets identified
in human neuron-like cells showed substantial and sig-
nificant overlap with those suggested by in vivo ChIP in
human fetal brain tissue in an independent study that
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exploited a different FOXP2 antibody.21(in this issue) Finally, by
studying ChIP targets in mutant mice, we have obtained
in vivo validation of both binding and functional regu-
lation in the embryonic brain.
Future research will assess the regulation of ChIP targets
during embryogenesis and in postnatal brain function by
use of relevant model systems, including rodents and song
birds.55 With regard to human studies, a subset of neural
targets of FOXP2 may represent novel candidates for in-
volvement in language-related phenotypes. Such genes
can be screened for genetic association and/or point mu-
tations in children affected with disorders like develop-
mental verbal dyspraxia, autism, and specific language im-
pairment. Thus, this work, which represents the first
isolation of direct neural targets regulated by FOXP2, dem-
onstrates how functional genomics may yield exciting
new insights into pathways that go awry in speech and
language disorders.
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